Akebia Therapeutics Inc — Cash Flow (NASDAQ:AKBA) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics

Quarterly Annual

Cash from operating activities 110.39 M252.97 M73.15 M23.38 M40.66 M67.99 M 67.99 M Cash from investing activities 40 M39.94 M114 K033 K7.93 M 7.93 M Cash from financing activities 231.72 M133.73 M14.6 M25.21 M49.66 M72.93 M 72.93 M Free cash flow 110.07 M252.91 M73.04 M23.38 M40.63 M67.7 M 67.7 M

新闻

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Akebia在Leerink会议上发言:战略聚焦Vafseo及产品管线

Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline

3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts - TipRanks.com

Ardelyx (ARDX) Reports Break-Even Earnings for Q4

Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Akebia Therapeutics签署新总部租约并修改高管离职协议

Akebia Therapeutics signs new headquarters lease and amends executive severance agreements

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA)

Akebia在罕见肾脏疾病试验中给首位患者用药

Akebia reports first patient dosed in rare kidney disease trial

Akebia Therapeutics begins phase 2 trial for rare kidney disease drug